Drug Trial Radar · NCT03520686
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
102
Actual
Start
May 18, 2018
Primary completion
Oct 13, 2025
Study completion Oct 13, 2025
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
Conditions
- Non Small Cell Lung Cancer
Interventions
NAI + PembrolizumabDrug
Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA): Dose: 15 µg/kg Route: Subcutaneous (SC) Schedule: Day 1 every 3 weeks Pembrolizumab: Dose: 200 mg Route: Intravenous (IV) Schedule: Day 1 every 3 weeks
NAI + Nivolumab + IpilimumabDrug
Nogapendekin alfa inbakicept (NAI): Dose: 15 µg/kg Route: SC Schedule: Days 1 and 22 every 6 weeks Nivolumab: Dose: 3 mg/kg Route: IV Schedule: Days 1, 15, and 29 every 6 weeks Ipilimumab: Dose: 1 mg/kg Route: IV Schedule: Day 1 every 6 weeks
NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or PaclitaxelDrug
Induction (Cycles 1-4, q3w): Carboplatin: AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV or Paclitaxel 200 mg/m² IV (Investigator's choice), Day 1 For nab-paclitaxel only: additional 100 mg/m² IV on Days 8 and 15 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1
Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAIDrug
Induction (Cycles 1-4, q3w): Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1
Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAIDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1
Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAIDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Paclitaxel 175 or 200 mg/m² IV (Investigator's choice), Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1
Carboplatin + Nab-paclitaxel + Atezolizumab + NAIDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV on Days 1, 8, and 15 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1
PembrolizumabDrug
Pembrolizumab 200 mg IV, Day 1 every 3 weeks
Pembrolizumab + Carboplatin + Nab-paclitaxel or PaclitaxelDrug
Induction (Cycles 1-4, q3w): Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV or Paclitaxel 200 mg/m² IV, Day 1 For nab-paclitaxel only: additional 100 mg/m² IV on Days 8 and 15 Pembrolizumab 200 mg IV, Day 1 Maintenance (Cycles ≥5, q3w): Pembrolizumab 200 mg IV, Day 1
Drug: Cisplatin/Carboplatin and Pemetrexed plus PembrolizumabDrug
Induction (Cycles 1-4, q3w): Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Maintenance (q3w): Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1
Cisplatin/Carboplatin and Pemetrexed plus AtezolizumabDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1
Carboplatin and Paclitaxel plus Atezolizumab and BevacizumabDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Paclitaxel 175 or 200 mg/m² IV, Day 1 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1
Carboplatin and Nab-paclitaxel plus AtezolizumabDrug
Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV on Days 1, 8, and 15 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1
Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelDrug
Cycle length: 6 weeks Nogapendekin alfa inbakicept (NAI): 1.2 mg SC on Days 1, 15, and 29 of each cycle Nivolumab: 360 mg IV on Days 1 and 22 of each cycle Ipilimumab: 1 mg/kg IV on Day 1 of each cycle Carboplatin: AUC 6 IV on Days 1 and 22 of Cycle 1 only Nab-paclitaxel: 100 mg/m² IV on Days 1, 8, 15, 22, 29, and 36 of Cycle 1 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 24 Months
- Change in absolute lymphocyte count (ALC).Time frame: Significantly Higher ALC Values Over Time Between Experimental & Control Arms Through 27 Weeks
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Alaska Urological Institute - Alaska Clinical Research Center
Anchorage, Alaska
Genesis Cancer Center
Hot Springs, Arkansas
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Adventist Health Glendale
Glendale, California
MemorialCare Health System
Long Beach, California
Adventist Health White Memorial
Los Angeles, California
Hoag Memorial Hospital
Newport Beach, California
Desert Hematology Oncology Medical Group
Rancho Mirage, California
Memorial Healthcare
Hollywood, Florida
Baptist Health South Florida - Miami Cancer Institute
Miami, Florida
Healthcare Research Network
Tinley Park, Illinois
Baptist Health - Lexington
Lexington, Kentucky
Baptist Health Louisville
Louisville, Kentucky
Karmanos Cancer Center
Detroit, Michigan
Mercy Research Joplin
Joplin, Missouri
St. Vincent Frontier Cancer Center
Billings, Montana
Astera Cancer Care
East Brunswick, New Jersey
University of Rochester
Rochester, New York
Stony Brooke Medicine
Stony Brook, New York
Mercy Research Oklahoma City
Oklahoma City, Oklahoma
LeHigh Valley
Allentown, Pennsylvania
Gettysburg Cancer Center
Gettysburg, Pennsylvania
Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)
Charleston, South Carolina
Saint Francis Cancer Center/Bon Secours St. Francis Health System
Greenville, South Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
University of Tennessee Medical Center
Knoxville, Tennessee
Baptist Cancer Center
Memphis, Tennessee
Texas Oncology-Austin
Austin, Texas
Texas Oncology-Bedford
Bedford, Texas
Oncology Consultants, PA
Houston, Texas
Bon Secours Richmond
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.